Proficiency Results From Your Peers at EULAR 2018 and Beyond

Beginning in 2016, RMEI created multiple accredited online educational programs focused on rheumatoid arthritis (RA) and designed for rheumatologists. The 2019 EULAR symposium was a unique opportunity to present the outcomes findings, from both the 2018 symposium and online courses, to the assembled rheumatologists within the context of addressing factors underlying ongoing educational gaps.

Presented at

Alliance Industry Summit (AIS), virtual, May 20, 2020. Awarded “Best in Class”

Share Educational Resource

Acknowledgement & Partners

This symposium (2019) and the previous (2018) were both supported by educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals.

RMEI Educational Outcomes

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we’ve learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Research with Preliminary Data – research projects that have collected data and are in the process of analyzing that data against the project’s hypothesis or objectives.
Presentation Year: 2021
Presented at: Accreditation Countil for Continuing Medical Education (ACCME), Society for Academic CME (SACME)
View Details

An Inflammatory Bowel Disease (IBD) Decision Support Tool Predicts Drug Specific Remission and Improves Provider Mastery in Treatment Selection

The CDST is unique among point-of-care tools in that it provides differential predictions for endoscopic remission with vedolizumab, adalimumab, and tofacitinib. This tool, which has the potential to improve patient outcomes, was supported and disseminated via web-based education. Findings from data collected during the 3 successive years of programming to-date revealed a significant increase in clinical mastery. Ultimately, clinicians engaged with this patient population who have participated in the education are more likely to use the tool regularly and correctly, as well as disseminating it amongst their colleagues.​
Presentation Year: 2023
Presented at: Digestive Disease Week (DDW)
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
Presentation Year: 2021
Presented at: Accreditation Countil for Continuing Medical Education (ACCME), Digestive Disease Week (DDW)
View Details

How Education Facilitated Uptake of a Novel Point of Care Decision Aid in IBD: The IBD Clinical Decision Support Tool

ACG 2023 Poster: There has been a progressive increase in the frequency of CDST usage between October 2019 and August 2023. 30,172 patient scenarios have been input into the IBD CDST to date. ​Serial education facilitated the real time observation of increases in clinician empowerment via course content adapted to meet demonstrated need.​ In real terms, learners pivoted their demonstrated mastery (243% overall improvement in correctness and confidence in their correctness) into substantially increased usage of the tool and by extension improved clinical efficacy. As of the last survey clinicians demonstrable appreciation of the value of the tool is their organic peer to peer dissemination of the IBD CDST.
Presentation Year: 2023
Presented at: American Gastroenterology Association (AGA)
View Details

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

The incidence of cutaneous squamous cell carcinoma (cSCC) is growing in the United States and epidemiologic data are likely to have underestimated the burden of the disease. New therapies are emerging for the management of advanced/unresectable cSCC that have the potential to alter outcomes. Clinicians need to be made aware of these new options and how they can be integrated into clinical practice. Dermatologists and Mohs surgeons will need to identify patients who are not surgical candidates and engage a multidisciplinary team to discuss systemic options, such as immunotherapy and optimal management approaches. To address the challenges facing clinicians in the appropriate alignment of treatment to patient, a 3-activity curriculum was developed. This curriculum was hosted online for one year, and findings from this education will be used to develop future content.
Presentation Year: 2020
Presented at: European Association of Dermato Oncology (EADO)
View Details

Multi-Year Analysis of Transplant Education 2016-2018

Over a 3-year period from 2016 to 2018, RMEI produced 10 live and 5 enduring online medical education courses that addressed optimal strategies for managing AMR and CMV in SOT patients, and CMV in HSCT patients. The education targeted both domestic and international audiences. Key: antibody-mediated rejection (AMR); cytomegalovirus (CMV); hematopoietic stem cell transplantation (HSCT); solid organ transplantation (SOT).
Presentation Year: 2019
Presented at: American Board of Medical Specialties (ABMS)